Eatontown, NJ, October 4, 2018 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) today announced the appointment of Samuel (Sam) Park as Global Head of Intellectual Property (IP) and General Counsel for the US, effective immediately.
4 October 2018
Corporate, Press Release
Mr. Park joins Hikma from Winston & Strawn LLP where he advised leading pharmaceutical companies on a variety of legal and intellectual property issues, from determining the appropriate IP strategies to litigating patent-protected pharmaceutical products. Mr Park will be based in the US.
Commenting on the appointment, Hussein Arkhagha, Hikma’s global General Counsel, said, “We are very excited that Sam has joined Hikma. He brings a wealth of legal experience and has an impressive record of challenging patents. Sam will play a pivotal role in enhancing our R&D program, enabling us to bring more differentiated products to the market.”
Commenting on his appointment, Mr. Park said, “Hikma has a strong legacy and has been investing in its people and capabilities to prepare for its next phase of growth. I share the company’s enthusiasm for the future and look forward to helping Hikma achieve its ambitions.”
Mr. Parks holds a B.A. in Biological Sciences from the University of Chicago and a J.D., magna cum laude, from Loyola University School of Law. He is licensed to practice in Illinois, New Jersey, New York, and the United States Patent & Trademark Office.